Drug Database
N06DA03 rivastigmine
Approved by UK Medicines & Healthcare Products Regulatory Agency & the European Medicines Agency.
- POM Almuriva 13.3 mg/24 h transdermal patch
- POM Almuriva 4.6 mg/24h transdermal patch
- POM Almuriva 9.5 mg/24h transdermal patch
- POM Alzest 13.3 mg/24 h Transdermal Patch
- POM Alzest 4.6mg/24h Transdermal Patch
- POM Alzest 9.5mg/24h Transdermal Patch
- POM Exelon 4.6 mg/24h, 9.5 mg/24h, 13.3 mg/24h transdermal patch
- POM Nimvastid 1.5 mg hard capsules
- POM Nimvastid 3 mg hard capsules
- POM Nimvastid 4.5 mg hard capsules
- POM Nimvastid 6 mg hard capsules
- POM Prometax 4.6 mg/24 h, 9.5 mg/24 h and 13.3 mg/24 h transdermal patch
- POM Prometax 9.5 mg/24 h transdermal patch
- POM Rivastigmine 2 mg/ml oral solution.
- POM Rivastigmine Dr. Reddy's 4.5mg hard Capsules
- POM Rivastigmine Dr. Reddys 1.5 mg hard Capsules
- POM Rivastigmine Dr. Reddys 3 mg hard Capsules
- POM Rivastigmine KRKA 1.5mg hard capsules
- POM Rivastigmine KRKA 3mg hard capsules
- POM Rivastigmine KRKA 4.5mg hard capsules
- POM Rivastigmine KRKA 6mg hard capsules
- POM Rivastigmine Mylan 1.5 mg hard capsules
- POM Rivastigmine Mylan 3 mg hard capsules
- POM Rivastigmine Mylan 4.5 mg hard capsules
- POM Rivastigmine Rosemont 2mg/ml Oral Solution
- POM Rivastigmine Sandoz 1.5 mg hard capsules (Great Britain)
- POM Rivastigmine Sandoz 2 mg/ml oral solution
- POM Rivastigmine Sandoz 3 mg hard capsules (Great Britain)
- POM Rivastigmine Sandoz 4.5 mg hard capsules (Great Britain)
- POM Rivastigmine Sandoz 6 mg hard capsules
- POM Rivastigmine Sandoz 6 mg hard capsules (Great Britain)
- POM Voleze 13.3mg/24h Transdermal Patch
- POM Zeyzelf twice weekly 4.6 mg/24 h transdermal patch
- POM Zeyzelf twice weekly 9.5 mg/24 h transdermal patch
Learning Zones
Disclaimer
The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.
Medthority will not be held liable for explicit or implicit errors, or missing data.
Drug Licencing
Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).